Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Abstract Background Epidermal growth factor receptor (EGFR)-mutated lung cancer constitutes a major subgroup of non-small cell lung cancer (NSCLC) and osimertinib is administrated as first-line treatment. However, most patients with osimertinib treatment eventually relapse within one year. The under...

Full description

Bibliographic Details
Main Authors: Shaocong Wu, Min Luo, Kenneth K. W. To, Jianye Zhang, Chaoyue Su, Hong Zhang, Sainan An, Fang Wang, Da Chen, Liwu Fu
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Molecular Cancer
Subjects:
Wild type EGFR
Exosomes
Osimertinib
NSCLC
Acquired resistance
Online Access:https://doi.org/10.1186/s12943-021-01307-9

Internet

https://doi.org/10.1186/s12943-021-01307-9

Similar Items